{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:03:41Z","timestamp":1768521821044,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"DOI":"10.7759\/cureus.26267","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:01:29Z","timestamp":1656036089000},"source":"Crossref","is-referenced-by-count":3,"title":["SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review"],"prefix":"10.7759","author":[{"given":"Rabia Salman","family":"Mahfooz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Khuzzaim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam","family":"Al Hennawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-215340","article-title":"Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin","volume":"2016","author":"Rashid O","year":"2016","unstructured":"Rashid O, Farooq S, Kiran Z, Islam N. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin. BMJ Case Rep. 2016, 2016:bcr2016215340. 10.1136\/bcr-2016-215340","journal-title":"BMJ Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro JF","year":"1973","unstructured":"Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J. 1973, 2:578-80. 10.1136\/bmj.2.5866.578","journal-title":"Br Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.172268","article-title":"Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: clinical perspectives","volume":"20","author":"John M","year":"2016","unstructured":"John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: clinical perspectives. Indian J Endocrinol Metab. 2016, 20:22-31. 10.4103\/2230-8210.172268","journal-title":"Indian J Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros A","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, et al.. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020, 173:417-25. 10.7326\/M20-0289","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.10.2819","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","volume":"126","author":"Davidson JA","year":"2014","unstructured":"Davidson JA, Kuritzky L. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Postgrad Med. 2014, 126:33-48. 10.3810\/pgm.2014.10.2819","journal-title":"Postgrad Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1797","article-title":"Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin","volume":"39","author":"Roach P","year":"2016","unstructured":"Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care. 2016, 39:e3. 10.2337\/dc15-1797","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0728","article-title":"A case of euglycemic diabetic ketoacidosis following long-term empagliflozin therapy","volume":"39","author":"Farjo PD","year":"2016","unstructured":"Farjo PD, Kidd KM, Reece JL. A case of euglycemic diabetic ketoacidosis following long-term empagliflozin therapy. Diabetes Care. 2016, 39:e165-6. 10.2337\/dc16-0728","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke KR","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017, 37:187-94. 10.1002\/phar.1881","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini E","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al.. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014, 124:499-508. 10.1172\/JCI72227","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2020.11.009","article-title":"Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature","volume":"7","author":"Mistry S","year":"2021","unstructured":"Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep. 2021, 7:17-9. 10.1016\/j.aace.2020.11.009","journal-title":"AACE Clin Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.10.001","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report","volume":"54","author":"Brown F","year":"2018","unstructured":"Brown F, McColl T. Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report. J Emerg Med. 2018, 54:109-11. 10.1016\/j.jemermed.2017.10.001","journal-title":"J Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011056","article-title":"Euglycemic diabetic ketoacidosis caused by dapagliflozin: a case report","volume":"97","author":"Chou YM","year":"2018","unstructured":"Chou YM, Seak CJ, Goh ZN, Seak JC, Seak CK, Lin CC. Euglycemic diabetic ketoacidosis caused by dapagliflozin: a case report. Medicine (Baltimore). 2018, 97:e11056. 10.1097\/MD.0000000000011056","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos A","year":"2019","unstructured":"Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med. 2019, 12:27. 10.1186\/s12245-019-0240-0","journal-title":"Int J Emerg Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4384","article-title":"Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature","volume":"11","author":"Gajjar K","year":"2019","unstructured":"Gajjar K, Luthra P. Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature. Cureus. 2019, 11:e4384. 10.7759\/cureus.4384","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020228","article-title":"Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report","volume":"99","author":"Lee IH","year":"2020","unstructured":"Lee IH, Ahn DJ. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report. Medicine (Baltimore). 2020, 99:e20228. 10.1097\/MD.0000000000020228","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616663231","article-title":"Canagliflozin-induced diabetic ketoacidosis: case report and review of the literature","volume":"4","author":"Turner J","year":"2016","unstructured":"Turner J, Begum T, Smalligan RD. Canagliflozin-induced diabetic ketoacidosis: case report and review of the literature. J Investig Med High Impact Case Rep. 2016, 4:2324709616663231. 10.1177\/2324709616663231","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8832833","article-title":"A case of diabetic ketoacidosis in a patient on an SGLT2 inhibitor and a ketogenic diet: a critical trio not to be missed","volume":"2020","author":"Steinmetz-Wood S","year":"2020","unstructured":"Steinmetz-Wood S, Gilbert M, Menson K. A case of diabetic ketoacidosis in a patient on an SGLT2 inhibitor and a ketogenic diet: a critical trio not to be missed. Case Rep Endocrinol. 2020, 2020:8832833. 10.1155\/2020\/8832833","journal-title":"Case Rep Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102116-sglt-2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-a-case-report-and-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:43Z","timestamp":1707507463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102116-sglt-2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-a-case-report-and-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.26267","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}